questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Indolizine
Indolizidines
Alcaloïdes indoliques
Alcaloïdes formés par condensation de sécologanine et de tryptamine
Alcaloïdes de Vinca
Vinblastine
Vinblastine : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
2
Vinblastine
Cancer
Diagnostic médical
Tests de laboratoire
Imagerie médicale
Vinblastine
Symptômes
2
Effets secondaires
Vinblastine
Nausées
Douleur
Vinblastine
Effets indésirables
Prévention
2
Prévention du cancer
Vinblastine
Traitement
Effets secondaires
Vinblastine
Médicaments antiémétiques
Traitements
2
Lymphome
Cancer du poumon
Vinblastine
Administration intraveineuse
Vinblastine
Traitement du cancer
Complications
2
Complications
Vinblastine
Infections
Moelle osseuse
Vinblastine
Dépression médullaire
Facteurs de risque
2
Facteurs de risque
Vinblastine
Maladies cardiaques
Vinblastine
Pédiatrie
Traitement du cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Vinblastine : Questions médicales les plus fréquentes",
"headline": "Vinblastine : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Vinblastine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-05-10",
"dateModified": "2025-05-05",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Vinblastine"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Alcaloïdes de Vinca",
"url": "https://questionsmedicales.fr/mesh/D014748",
"about": {
"@type": "MedicalCondition",
"name": "Alcaloïdes de Vinca",
"code": {
"@type": "MedicalCode",
"code": "D014748",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.496.500.500.681.827"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Vinblastine",
"alternateName": "Vinblastine",
"code": {
"@type": "MedicalCode",
"code": "D014747",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "None None",
"url": "https://questionsmedicales.fr/author/None%20None",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Christine Chevreau",
"url": "https://questionsmedicales.fr/author/Christine%20Chevreau",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine, Oncopole, Toulouse, France."
}
},
{
"@type": "Person",
"name": "Stéphane Culine",
"url": "https://questionsmedicales.fr/author/St%C3%A9phane%20Culine",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr."
}
},
{
"@type": "Person",
"name": "Gwenaelle Gravis",
"url": "https://questionsmedicales.fr/author/Gwenaelle%20Gravis",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France."
}
},
{
"@type": "Person",
"name": "Florence Joly",
"url": "https://questionsmedicales.fr/author/Florence%20Joly",
"affiliation": {
"@type": "Organization",
"name": "Department of Medical Oncology, François Baclesse Cancer Center, Caen, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "A review of artificial intelligence in mammography.",
"datePublished": "2022-05-15",
"url": "https://questionsmedicales.fr/article/35623118",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinimag.2022.05.005"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mammography in combination with breast ultrasonography versus mammography for breast cancer screening in women at average risk.",
"datePublished": "2023-03-31",
"url": "https://questionsmedicales.fr/article/36999589",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD009632.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Quality assurance in Mammography: An overview.",
"datePublished": "2023-06-19",
"url": "https://questionsmedicales.fr/article/37354771",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejrad.2023.110935"
}
},
{
"@type": "ScholarlyArticle",
"name": "A new breast phantom suitable for digital mammography, contrast-enhanced digital mammography and digital breast tomosynthesis.",
"datePublished": "2023-02-14",
"url": "https://questionsmedicales.fr/article/36696693",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1088/1361-6560/acb636"
}
},
{
"@type": "ScholarlyArticle",
"name": "Health inequities in mammography: A scoping review.",
"datePublished": "2023-01-09",
"url": "https://questionsmedicales.fr/article/36640712",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejrad.2023.110693"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Indolizine",
"item": "https://questionsmedicales.fr/mesh/D007212"
},
{
"@type": "ListItem",
"position": 6,
"name": "Indolizidines",
"item": "https://questionsmedicales.fr/mesh/D054836"
},
{
"@type": "ListItem",
"position": 7,
"name": "Alcaloïdes indoliques",
"item": "https://questionsmedicales.fr/mesh/D026121"
},
{
"@type": "ListItem",
"position": 8,
"name": "Alcaloïdes formés par condensation de sécologanine et de tryptamine",
"item": "https://questionsmedicales.fr/mesh/D046948"
},
{
"@type": "ListItem",
"position": 9,
"name": "Alcaloïdes de Vinca",
"item": "https://questionsmedicales.fr/mesh/D014748"
},
{
"@type": "ListItem",
"position": 10,
"name": "Vinblastine",
"item": "https://questionsmedicales.fr/mesh/D014747"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Vinblastine - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Vinblastine",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Vinblastine",
"description": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?\nQuels tests précèdent l'administration de vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Vinblastine",
"description": "Quels sont les effets secondaires courants de la vinblastine ?\nLa vinblastine provoque-t-elle des douleurs ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Vinblastine",
"description": "La vinblastine a-t-elle un rôle préventif dans le cancer ?\nPeut-on prévenir les effets secondaires de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Vinblastine",
"description": "Dans quels types de cancer la vinblastine est-elle utilisée ?\nComment la vinblastine est-elle administrée ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Vinblastine",
"description": "Quelles complications peuvent survenir avec la vinblastine ?\nLa vinblastine peut-elle affecter la moelle osseuse ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Vinblastine",
"description": "Qui est à risque d'effets indésirables avec la vinblastine ?\nLes enfants peuvent-ils prendre de la vinblastine ?",
"url": "https://questionsmedicales.fr/mesh/D014747?mesh_terms=Mammography#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment la vinblastine est-elle utilisée dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine n'est pas un outil de diagnostic, mais un traitement pour les cancers diagnostiqués."
}
},
{
"@type": "Question",
"name": "Quels tests précèdent l'administration de vinblastine ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins et d'imagerie sont effectués pour évaluer la maladie avant le traitement."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants de la vinblastine ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, vomissements, fatigue et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La vinblastine provoque-t-elle des douleurs ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut causer des douleurs musculaires ou articulaires, mais ce n'est pas systématique."
}
},
{
"@type": "Question",
"name": "La vinblastine a-t-elle un rôle préventif dans le cancer ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la vinblastine est un traitement et ne prévient pas le développement du cancer."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les effets secondaires de la vinblastine ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments antiémétiques peuvent aider à réduire les nausées causées par la vinblastine."
}
},
{
"@type": "Question",
"name": "Dans quels types de cancer la vinblastine est-elle utilisée ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour traiter les lymphomes, le cancer du poumon et le cancer du testicule."
}
},
{
"@type": "Question",
"name": "Comment la vinblastine est-elle administrée ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La vinblastine est généralement administrée par injection intraveineuse sous supervision médicale."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec la vinblastine ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des infections, des saignements et des problèmes neurologiques."
}
},
{
"@type": "Question",
"name": "La vinblastine peut-elle affecter la moelle osseuse ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut entraîner une dépression de la moelle osseuse, réduisant les globules blancs."
}
},
{
"@type": "Question",
"name": "Qui est à risque d'effets indésirables avec la vinblastine ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients avec des antécédents de maladies cardiaques ou hépatiques sont à risque accru."
}
},
{
"@type": "Question",
"name": "Les enfants peuvent-ils prendre de la vinblastine ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la vinblastine peut être administrée aux enfants, mais avec précaution et surveillance."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 05/05/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Publications dans "Vinblastine" :
Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2020-07-30
Doxorubicin, vinblastine, dacarbazine and lenalidomide for older Hodgkin lymphoma patients: final results of a German Hodgkin Study Group (GHSG) phase-I trial.
British journal of haematology
2018-12-28
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
4 publications dans cette catégorie
Affiliations :
Department of Medicine, Oncopole, Toulouse, France.
Publications dans "Vinblastine" :
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study.
The Lancet. Oncology
2019-07-19
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology Saint-Louis University Hospital, AP-HP, Paris, France. Electronic address: stephane.culine@aphp.fr.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Paoli Calmettes Institute, Marseille, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, François Baclesse Cancer Center, Caen, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Medical Oncology, Lucien Neuwirth Cancer Institute, Saint-Priest-en-Jarez, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
3 publications dans cette catégorie
Affiliations :
Department of Pathology, René Huguenin Curie Institute, Saint Cloud, France.
Publications dans "Vinblastine" :
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study.
Clinical genitourinary cancer
2021-02-24
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study.
The Lancet. Oncology
2023-12-21
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2022-03-07
2 publications dans cette catégorie
Affiliations :
Programme in Developmental and Stem Cell Biology, Division of Haematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Plant Production Department, College of Food and Agriculture Sciences, King Saud University, Riyadh 11451, Saudi Arabia.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Natural Product Biosynthesis, Max Planck Institute for Chemical Ecology, Jena, Germany.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Massachusetts General Hospital Cancer Center, Boston, MA.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Small Animal Clinical Sciences, Department of Veterinary Anatomy Physiology and Pathology, Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Chester High Rd, Neston CH64 7TE, UK.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Rehabilitation Medicine, Nagoya University Hospital, Nagoya, Japan.
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Department of Orthopaedic Surgery, Nagoya University Hospital, Nagoya, Japan.
Publications dans "Vinblastine" :
2 publications dans cette catégorie
Affiliations :
Laboratory of Bioanalysis, Department of Pharmaceutical Chemistry, Drug Analysis and Radiopharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland; Department of Applied Pharmacy, Medical University of Lodz, ul. Muszyńskiego 1, 90-151, Lodz, Poland.
Publications dans "Vinblastine" :
Breast cancer is the most common cancer among women worldwide. Mammography is the most widely used modality to detect breast cancer. Over the past decade, computer aided detection (CAD) powered by art...
Screening mammography can detect breast cancer at an early stage. Supporters of adding ultrasonography to the screening regimen consider it a safe and inexpensive approach to reduce false-negative rat...
To assess the comparative effectiveness and safety of mammography in combination with breast ultrasonography versus mammography alone for breast cancer screening for women at average risk of breast ca...
We searched the Cochrane Breast Cancer Group's Specialised Register, CENTRAL, MEDLINE, Embase, the World Health Organization International Clinical Trials Registry Platform (WHO ICTRP), and ClinicalTr...
For efficacy and harms, we considered randomised controlled trials (RCTs) and controlled non-randomised studies enrolling at least 500 women at average risk for breast cancer between the ages of 40 an...
Two review authors screened abstracts and full texts, assessed risk of bias, and applied the GRADE approach. We calculated the risk ratio (RR) with 95% confidence intervals (CI) based on available eve...
We included eight studies: one RCT, two prospective cohort studies, and five retrospective cohort studies, enrolling 209,207 women with a follow-up duration from one to three years. The proportion of ...
Based on one study in women at average risk of breast cancer, ultrasonography in addition to mammography leads to more screening-detected breast cancer cases. For women with dense breasts, cohort stud...
Since 1989, hundreds of thousands of lives have been saved worldwide by the widespread use of screening mammography alongside new developments in breast cancer treatment [1]. The ability of screening ...
Our objective is to report a new breast phantom that provides the objective assessment for three types of clinical mammography, i.e. digital mammography (DM), contrast-enhanced digital mammography (CE...
The objective of this scoping review is to chart the existing evidence on health inequities related to mammography and identify existing knowledge gaps to guide future research....
This scoping review followed guidelines from the Joanna Briggs Institute and the PRISMA extension for scoping reviews. In July 2022, we searched PubMed and Ovid Embase for published articles on mammog...
Following screening, our sample consisted of 128 studies. Our findings indicate that mammography screening was less likely in historically marginalized groups, patients who live in rural areas, and in...
This scoping review highlights the gaps in inequities research regarding mammography, as well as the limited consensus across findings. To bridge existing research gaps, we recommend research into the...
Breast cancer is the leading female cancer worldwide with a high mortality rate. Early detection of the suspicious lesion is crucial for better prognosis. Higher breast density decreases the sensitivi...
This was a cross sectional study including 125 females who underwent diagnostic mammogram in a tertiary care center. The mammograms were evaluated and the patients were scanned by ultrasound and categ...
The heterogeneously dense breast in diagnostic mammography corresponded to the heterogenous- fibroglandular breast in ultrasonography. In majority, ultrasound increased the BIRADS category for the les...
Ultrasound was useful in evaluation of dense breasts with ACR-BIRADS 0 and 3 in diagnostic mammogram. For category 3 and 4 in diagnostic mammogram, ultrasound showed category 1 or 2 lesions which aide...
In Germany, all women aged 50-69 have been invited to biennial mammography screening since 2009. We aimed to assess longitudinal adherence over ten years in women aged 50 in 2009 and characterize the ...
Using the German Pharmacoepidemiological Research Database (GePaRD, ~ 20% of the German population), we included women aged 50 in 2009 (baseline) with continuous health insurance coverage and without ...
Overall, 82,666 women were included. Of these, 27.6% never participated in the screening program, 15.1% participated 1-2 times, 31.7% participated 3-4 times and 25.6% participated regularly (5-6 times...
Using a large cohort based on claims data, this study provides novel insights into longitudinal adherence to the mammography screening program and the use of mammography outside of the program in Germ...
According to the guidelines, the mammograms obtained in a screening program must be evaluated to ensure that the quality of the images obtained is above 75% of score 1 (perfect and good) and less than...
Five radiographers evaluated a total of 1000 mammograms. One radiographer was an expert in assessing mammography images, while the other four evaluators had varying levels of experience. All images we...
The results from Fleiss' kappa showed fair agreement in the mediolateral oblique (MLO) projection in the first group of evaluators whereas the other results showed poor agreement. When comparing the r...
Based on our results, we can conclude that the agreement between all five raters was poor for both CC (κ = 0.165) and MLO (κ = 0.135) projections, based on the results of Fleiss' kappa statistic. The ...
Thus, the images are evaluated by a person, which has a high impact on subjectivity in the assessment of positioning in mammography. To achieve a more objective assessment of the images and the result...
Breast carcinoma is the second largest cancer in the world among women. Early detection of breast cancer has been shown to increase the survival rate, thereby significantly increasing patients' lifesp...
With modern technological advances in imaging, radial scars are more frequently encountered in clinical practice. The management of radial scars remains challenging due to associated upgrade to malign...